BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Total Debt

Short-term and long-term borrowings combined.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Total Debt · Q3 FY2026 · quarter ended Sep 2026

Total debt rises 108915.6% from a year ago

Total debt stood at $658.72B at the end of Q3 FY2026, up 108915.6% from a year earlier and up 15575.5% from the prior quarter. Over 3 fiscal years it compounded at -16.2% a year.

Context

  • Total debt amounted to 5.7% of total assets at the end of Q3 FY2026, down 2.2 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +108915.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$658.72B+15575.5% QoQ
Last fiscal yearDec 2025
$642.87M-1.0% YoY
Year agoSep 2025
$604.24M+108915.6% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+108915.6%——
1 year-1.0%——
3-year CAGR-16.2%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
642.87M USD
Year-over-year change
-1.0%
4-year CAGR
-12.4%

Total Debt vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +108915.6% is the highest of 11, against a peer median of +21.1%.
  • Total debt amounts to 5.7% of total assets for BMRN, versus a peer median of 25.7%.
BMRN Competitors
Total Debt for BMRN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$658.72B USD+108915.6%-16.2%5.7%
VRTXVertex Pharmaceuticals IncorporatedSep 2026$6.48B USD+253.1%+62.8%19.8%
BBIOBridgeBio Pharma, Inc.Jun 2026$2.49B USD-6.8%+16.5%204.9%
IONSIonis Pharmaceuticals, Inc.Sep 2026$2.15B USD+44.5%+24.1%73.9%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$1.27B USD-2.3%-1.1%22.8%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$1.2B USD+3035.4%+243.1%92.6%
PTCTPTC Therapeutics, Inc.Jun 2026$696.47M USD+79.4%+22.8%21.4%
TVTXTravere Therapeutics, Inc.Sep 2026$616.16M USD+86.9%-6.9%72.6%
INSMInsmed IncorporatedJun 2026$579.88M USD-22.0%-13.3%27.6%
ASNDAscendis Pharma A/SSep 2026€447.81M EUR-45.0%+12.2%18.4%
PHARPharming Group N.V.Mar 2026$116.21M USD-2.5%-11.4%23.7%
Peer median (excluding BMRN) —+21.1%+14.4%25.7%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents587.28M724.53M755.13M942.84M1.31B
Short-term Investments426.6M567.01M318.68M194.86M248.93M
Net Receivables373.4M461.32M633.7M660.54M908.21M
Inventory776.67M894.08M1.11B1.23B1.3B
Other Current Assets110.44M104.52M141.39M201.53M185.78M
Total Current Assets2.27B2.75B2.96B3.23B3.95B
Property, Plant & Equipment (Net)1.04B1.07B1.07B1.04B952.51M
Goodwill196.2M196.2M196.2M196.2M196.2M
Intangible Assets388.65M338.57M294.7M255.28M213.84M
Long-term Investments507.79M333.84M611.14M521.24M498.21M
Tax Assets1.45B1.51B1.55B1.49B1.51B
Other Non-current Assets152.12M176.24M171.54M251.39M277.05M
Total Non-current Assets3.73B3.62B3.89B3.76B3.64B
Total Assets6B6.38B6.84B6.99B7.59B
Account Payables199.68M231.24M315.51M235.4M312.77M
Short-term Debt00493.88M23.07M8.69M
Tax Payables1.21M16.21M2.65M12.57M0
Deferred Revenue6.96M711K4.62M1.37M0
Other Current Liabilities258.94M236.1M234.92M132.07M210.72M
Total Current Liabilities546.5M588.88M1.18B606.99M759.03M
Long-term Debt1.08B1.08B593.1M595.14M597.18M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities113.53M100.02M119.94M97.57M113.8M
Total Non-current Liabilities1.19B1.18B713.03M723.96M747.99M
Total Liabilities1.74B1.77B1.89B1.33B1.51B
Common Stock184K186K189K191K192K
Retained Earnings(930.76M)(789.2M)(621.55M)(194.7M)154.21M
Accumulated OCI14.43M(3.87M)(28.79M)61.65M(13.47M)
Other Stockholders Equity(9.69M)(8.86M)(9.86M)(11.23M)(10.51M)
Minority Interest00000
Total Equity4.27B4.6B4.95B5.66B6.09B
Total Debt1.09B1.09B1.1B649.47M642.87M
Net Debt502.27M368.86M340.62M(293.38M)(668.81M)

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.